Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells $138,600.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the sale, the insider now directly owns 122,279 shares in the company, valued at approximately $1,694,786.94. The trade was a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA traded down $0.77 during trading hours on Wednesday, hitting $13.43. 779,371 shares of the stock were exchanged, compared to its average volume of 729,021. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. The company's 50 day moving average is $12.76 and its two-hundred day moving average is $14.79. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $8.46 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. Analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CNTA has been the topic of several research analyst reports. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 price objective on the stock. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price on the stock. Morgan Stanley restated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $27.89.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd lifted its holdings in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after buying an additional 3,194 shares during the period. Osterweis Capital Management Inc. bought a new position in Centessa Pharmaceuticals in the first quarter valued at approximately $47,000. Barclays PLC grew its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth $147,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.